Ontology highlight
ABSTRACT: Objective
To describe the clinico-radiologic outcome of MS patients with natalizumab-related progressive multifocal leukoencephalopathy (Nz-PML) surviving and receiving disease-modifying therapy (DMT).Methods
We describe clinical and radiologic evolution of Nz-PML survivors in an observational retrospective multicenter cohort to clarify the effect of different subsequent MS DMT strategies. Twenty-three patients from 11 centers were analyzed. Outcomes were (1) clinical efficacy of post-PML MS DMT, (2) radiologic efficacy of post-PML MS DMT, (3) radiologic evolution of PML lesion, and (4) disability progression.Results
There was no clinical worsening of PML symptoms with a stability of Expanded Disability Status Scale at the last follow-up. No relapse was reported with fingolimod and dimethyl fumarate. No radiologic worsening of Nz-PML lesion was observed at the end of the follow-up.Conclusion
In this large cohort of patients with Nz-PML, MS therapies given after Nz discontinuation were not associated with PML worsening. A larger cohort with longer follow-up will be necessary to confirm this therapeutic strategy.
SUBMITTER: Maillart E
PROVIDER: S-EPMC5462603 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Maillart Elisabeth E Vidal Jean-Sebastien JS Brassat David D Stankoff Bruno B Fromont Agnès A de Sèze Jérôme J Taithe Frédéric F Clavelou Pierre P Bourre Bertrand B Delvaux Valérie V Rico Audrey A Labauge Pierre P Tourbah Ayman A Lebrun Christine C Pelletier Jean J Moreau Thibault T Louapre Céline C Lubetzki Catherine C Papeix Caroline C
Neurology(R) neuroimmunology & neuroinflammation 20170414 3
<h4>Objective</h4>To describe the clinico-radiologic outcome of MS patients with natalizumab-related progressive multifocal leukoencephalopathy (Nz-PML) surviving and receiving disease-modifying therapy (DMT).<h4>Methods</h4>We describe clinical and radiologic evolution of Nz-PML survivors in an observational retrospective multicenter cohort to clarify the effect of different subsequent MS DMT strategies. Twenty-three patients from 11 centers were analyzed. Outcomes were (1) clinical efficacy of ...[more]